help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published ahead of print on October 13, 2005, doi:10.1164/rccm.200507-1144OC

Am. J. Respir. Crit. Care Med., Volume 173, Number 2, January 2006, 180-187

A more recent version of this article appeared on January 15, 2006
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200507-1144OCv1
173/2/180    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Keogh, K. A
Right arrow Articles by Specks, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Keogh, K. A
Right arrow Articles by Specks, U.

Submitted on July 25, 2005
Accepted on October 7, 2005

Rituximab for Refractory Wegener's Granulomatosis: Report of A Prospective, Open-Label Pilot Trial

Karina A Keogh1, Steven R Ytterberg2, Fernando C Fervenza3, Kimberly A Carlson1, Darrell R Schroeder4, and Ulrich Specks1*

1 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA, 2 Division of Rheumatology, Mayo Clinic, Rochester, MN, USA, 3 Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA, 4 Division of Biostatistics, Mayo Clinic, Rochester, MN, USA

* To whom correspondence should be addressed. E-mail: specks.ulrich{at}mayo.edu.

Rationale: Standard therapy for Wegener's granulomatosis is fraught with substantial toxicity and not always effective. B lymphocytes have been implicated in the pathogenesis of Wegener's granulomatosis. Their depletion has been proposed as salvage therapy for refractory disease. Earlier encouraging reports are confounded by concomitant immunosuppressive medications and include only limited available biomarker data. Objectives: To evaluate efficacy and safety of rituximab for remission induction in refractory Wegener's granulomatosis. Methods: Prospective open-label pilot trial in 10 patients followed for one year. Included were patients with active severe ANCA-associated vasculitis, ANCA-positivity, resistance to - or intolerance of cyclophosphamide. The remission induction regimen consisted of oral prednisone (1 mg/kg/day) and four weekly infusions of rituximab (375mg/m2). Prednisone was tapered and discontinued over 5 months. Failure to achieve remission, a clinical flare in the absence of B lymphocytes, or inability to complete the glucocorticoid taper, were considered treatment failures. Main Results: Three women and 7 men, median age of 57 (25-72), were enrolled. All had ANCA reacting with proteinase 3. The median activity score at enrollment was 6 (5-10). All patients tolerated rituximab well, achieved swift B lymphocyte depletion and complete clinical remission (activity score=0) by 3 months, and were tapered off glucocorticoids by 6 months. Five patients were retreated with rituximab alone for recurring/rising ANCA titers according to protocol. One patient experienced a clinical flare after B lymphocyte reconstitution. Conclusions: In this cohort, rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis.
Key words: Wegener granulomatosis, ANCA, rituximab, treatment




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. J. Ferraro, S. W. Smith, D. Neil, and C. O.S. Savage
Relapsed Wegener's granulomatosis after rituximab therapy--B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood
Nephrol. Dial. Transplant., September 1, 2008; 23(9): 3030 - 3032.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
S. Lovric, U. Erdbruegger, P. Kumpers, A. Woywodt, C. Koenecke, H. Wedemeyer, H. Haller, and M. Haubitz
Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: single centre experience with 15 patients
Nephrol. Dial. Transplant., August 6, 2008; (2008) gfn430v1.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
F. C. Fervenza, S. Sethi, and U. Specks
Idiopathic Membranous Nephropathy: Diagnosis and Treatment
Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 905 - 919.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
A. D. Salama, H. T. Cook, C. D. Pusey, and R. J. Pepper
A Case of Treated ANCA-Associated Vasculitis with Recurrent Renal Failure
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 637 - 645.
[Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
O Flossmann, P Bacon, K de Groot, D Jayne, N Rasmussen, P Seo, K Westman, and R Luqmani
Development of comprehensive disease assessment in systemic vasculitis
Postgrad. Med. J., March 1, 2008; 84(989): 143 - 152.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
X. Bosch, A. Guilabert, G. Espinosa, and E. Mirapeix
Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review
JAMA, August 8, 2007; 298(6): 655 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. Jayne
Leflunomide versus methotrexate in Wegener's granulomatosis
Rheumatology, July 1, 2007; 46(7): 1047 - 1048.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
P. M Stassen, J. W. Cohen Tervaert, and C. A Stegeman
Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide
Ann Rheum Dis, June 1, 2007; 66(6): 798 - 802.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. U. Wells and C. M. Hogaboam
Update in Diffuse Parenchymal Lung Disease 2006
Am. J. Respir. Crit. Care Med., April 1, 2007; 175(7): 655 - 660.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
S. R Sangle, G. R V Hughes, and D. P D'Cruz
Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects
Ann Rheum Dis, April 1, 2007; 66(4): 564 - 565.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al.
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
Ann Rheum Dis, April 1, 2007; 66(4): 470 - 475.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. F. Wong
Reply
Nephrol. Dial. Transplant., March 1, 2007; 22(3): 959 - 959.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
O. Flossmann, P. Bacon, K. de Groot, D. Jayne, N. Rasmussen, P. Seo, K. Westman, and R. Luqmani
Development of comprehensive disease assessment in systemic vasculitis
Ann Rheum Dis, March 1, 2007; 66(3): 283 - 292.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
C. F. Wong
Rituximab in refractory antineutrophil cytoplasmic antibody-associated vasculitis: what is the current evidence?
Nephrol. Dial. Transplant., January 1, 2007; 22(1): 32 - 36.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
O Flossmann, R B Jones, D R W Jayne, and R A Luqmani
Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?
Ann Rheum Dis, July 1, 2006; 65(7): 841 - 844.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. D. Morgan, L. Harper, J. Williams, and C. Savage
Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis
J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1224 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. A. Keogh, F. C. Fervenza, and U. Specks
Rituximab in Refractory Wegener's Granulomatosis: Favorable or Not?
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 816 - 816.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. M. Aries, P. Lamprecht, and W. L. Gross
Rituximab in refractory Wegener's granulomatosis: favorable or not?
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 815a - 8816.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society